2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 201

High Rate of Autoimmune Manifestations During Idiopathic CD4 Lymphocytopenia
Abstract Number: 2179

High Resolution CT Findings and Concomitant Nontuberculosis Mycobacterial Infection (NTM) in Patients with the Diagnosis of Primary Sjogren’s Syndrome Evaluated At a Respiratory Referral Center
Abstract Number: 1007

High Resolution Peripheral Quantitative CT Detects Marked Differences in Metacarpal Head and Shaft and Ultra-Ultra-Distal Radius Bone Volumetric Density and Microstructure in Early Rheumatoid Arthritis
Abstract Number: 2541

High Risk of Intensive Care Unit Admission in Rheumatoid Arthritis Patients: A Population Based Study
Abstract Number: 2251

High Sensitivity C-Reactive Protein, Disease Activity and Cardiovascular Risk Factors in Systemic Lupus Erythematosus
Abstract Number: 964

High-Energy Extracorporeal Shock Wave Therapy Is Effective for Treating Chronic Calcific Tendonitis of the Shoulder: A Meta-Analysis
Abstract Number: 1651

Higher Corticosteroid Doses Early in Disease Have A Long-Term Influence On Metabolic Syndrome in Systemic Lupus Erythematosus: Data from an International Inception Cohort
Abstract Number: 2396

Higher Homocysteine Levels Are Associated with Ischemic Arterial Events Rather Than Disease Activity and the Extension of Arterial Involvement in Takayasu Arteritis
Abstract Number: 708

Histological Features of Localized Scleroderma‘en Coup De Sabre‘: A Study of 16 Cases
Abstract Number: 2553

Histological, Serological and Clinical Changes in Response to Abatacept Treatment of Sjögren’s Syndrome
Abstract Number: 1444

HLA-DR3 Controls Autoantibody Response to Sm in NZM2328.DR3+.AE0 Transgenic Mice
Abstract Number: 1937

HLA-DRB1*0101/*0405 Is Associated with Susceptibility to Anti-MDA5 Antibody-Positive Dermatomyositis in the Japanese Population
Abstract Number: 2400

Hospital for Special Surgery Osteoarthritis Wellness Initiative: the Impact of a Hospital-Based Exercise Program On Osteoarthritis
Abstract Number: 1387

Hospitalizations and Reasons for Admission in a Clinical SLE Cohort
Abstract Number: 283

Hospitalizations for Patients with Chilhood-Onset Systemic Lupus Erythematosus in the Pediatric Health Information System Databse

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].